Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Sponsor
Samsung Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02461849
Collaborator
(none)
14
1
1
103.9
0.1

Study Details

Study Description

Brief Summary

KIT is a receptor tyrosine kinase that binds to stem-cell factor (SCF), activating a series of downstream effector pathways. KIT is an established therapeutic target in cancer with activating mutations of KIT, such as gastrointestinal stromal tumors (GIST), and significant benefit is achieved with various small molecule inhibitors of KIT such as imatinib mesylate. Moreover, there is increasing evidence implicating KIT mutations as tractable therapeutic targets in melanoma. Additional information is required to characterize the functional role of low-frequency mutations in KIT and to determine whether amplification of wild type KIT is a real driver that can be targeted therapeutically. Except GIST and melanoma, other solid cancers were reported to have KIT mutation even in low frequency. A molecular profiling of the tumors of patients referred to the phase I clinic at the M.D. Anderson Cancer Center showed KIT mutation in 7 patients in total of 431 patients (2%).

Hence, the investigators planned this study to apply the molecularly targeted agent, imatinib to various types of cancers harboring KIT mutation or amplification.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II, Open-label, Study in Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Actual Study Start Date :
Apr 4, 2014
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Imatinib

Imatinib 400mg qd daily Until disease progression, patient's refusal

Drug: Imatinib
Imatinib 400mg qd daily

Outcome Measures

Primary Outcome Measures

  1. Response rate [expected average of 24 weeks]

    Response will be evaluated according to RECIST(Response Evaluation Criteria In Solid Tumors) 1.1 guidelines.Tumor responses will be assessed after the 2cycle chemotherapy and after completion of treatment. They should be classified as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD) according to the Revised Response Criteria for refractory, metastatic cancer harboring KIT mutation or amplification.

Secondary Outcome Measures

  1. Duration of response [expected average of 24 weeks]

  2. Progression-free survival [expected average of 24 weeks]

  3. Overall survival [expected average of 3years]

  4. Number of subjects with Adverse Events as a measure of safety [expected average of 24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. age ≥ 20

  2. advanced, refractory cancer patients who failed standard of care (SOC)

  3. KIT aberration: defined as mutation in exons 9, 11, 13, 17 or 18, or nanostring CNV by quantitative PCR (greater than 3 copies) or subject with specific sensitivity (Z-score<-1) to imatinib by Avatar scan whose disease has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy

  4. ECOG performance status of 0~2

  5. measurable or evaluable lesion per RECIST 1.1 criteria

  6. adequate marrow, hepatic, renal and cardiac functions

  • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy

  • Total serum bilirubin ≤ 1.5 x ULN

  • Absolute neutrophil count(ANC) ≥ 1,500/uL

  • Platelets ≥ 100,0000/uL

  • Hemoglobin ≥ 9.0 g/dL

  1. provision of a signed written informed consent
Exclusion Criteria:
  1. severe co-morbid illness and/or active infections

  2. pregnant or lactating women

  3. history of major surgery or radiotherapy within 4 weeks

  4. active CNS metastases not controllable with radiotherapy or corticosteroids (however, CNS metastases (except for leptomeningeal seeding) are allowed if controlled by gamma knife surgery or surgery or radiotherapy or steroid)

  5. known history of hypersensitivity to study drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 Samsung Medical Center Seoul Korea, Republic of

Sponsors and Collaborators

  • Samsung Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jeeyun Lee, MD,PhD, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT02461849
Other Study ID Numbers:
  • 2013-12-074
First Posted:
Jun 3, 2015
Last Update Posted:
Jun 15, 2022
Last Verified:
Jun 1, 2022
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2022